Header Logo

Connection

Saad Usmani to Risk Factors

This is a "connection" page, showing publications Saad Usmani has written about Risk Factors.
Connection Strength

0.370
  1. Patel JN, Robinson M, Jagosky M, Slaughter D, Arnall J, Jandrisevits E, Matusz-Fisher A, Atrash S, Paul B, Bhutani M, Voorhees P, Usmani SZ. Thromboembolism Incidence and Risk Factors in Multiple Myeloma After First Exposure to Immunomodulatory Drug-Based Regimens. Clin Lymphoma Myeloma Leuk. 2021 03; 21(3):188-198.e2.
    View in: PubMed
    Score: 0.089
  2. Jagosky MH, Usmani SZ. Extramedullary Disease in Multiple Myeloma. Curr Hematol Malig Rep. 2020 04; 15(2):62-71.
    View in: PubMed
    Score: 0.085
  3. Usmani SZ, Sawyer J, Rosenthal A, Cottler-Fox M, Epstein J, Yaccoby S, Sexton R, Hoering A, Singh Z, Heuck CJ, Waheed S, Chauhan N, Johann D, Abdallah AO, Muzaffar J, Petty N, Bailey C, Crowley J, van Rhee F, Barlogie B. Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma. Blood. 2013 Jun 06; 121(23):4753-7.
    View in: PubMed
    Score: 0.052
  4. Joseph JM, Hillengass J, Tang L, Lesokhin AM, Landgren O, Usmani SZ, Moysich KB, McCann SE, Shah UA. Dietary risk factors for monoclonal gammopathy of undetermined significance in a racially diverse population. Blood Adv. 2024 02 13; 8(3):538-548.
    View in: PubMed
    Score: 0.028
  5. Castro F, Parikh R, Eustaquio JC, Derkach A, Joseph JM, Lesokhin AM, Usmani SZ, Shah UA. Pre-diagnosis dietary patterns and risk of multiple myeloma in the NIH-AARP diet and health study. Leukemia. 2024 02; 38(2):438-441.
    View in: PubMed
    Score: 0.027
  6. Mateos MV, Kumar S, Dimopoulos MA, Gonz?lez-Calle V, Kastritis E, Hajek R, De Larrea CF, Morgan GJ, Merlini G, Goldschmidt H, Geraldes C, Gozzetti A, Kyriakou C, Garderet L, Hansson M, Zamagni E, Fantl D, Leleu X, Kim BS, Esteves G, Ludwig H, Usmani S, Min CK, Qi M, Ukropec J, Weiss BM, Rajkumar SV, Durie BGM, San-Miguel J. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). Blood Cancer J. 2020 10 16; 10(10):102.
    View in: PubMed
    Score: 0.022
  7. Atrash S, Robinson M, Slaughter D, Aneralla A, Brown T, Robinson J, Ndiaye A, Sprouse C, Zhang Q, Symanowski JT, Friend R, Voorhees PM, Usmani SZ, Bhutani M. Evolving changes in M-protein and hemoglobin as predictors for progression of smoldering multiple myeloma. Blood Cancer J. 2018 11 08; 8(11):107.
    View in: PubMed
    Score: 0.019
  8. Htut M, D'Souza A, Krishnan A, Bruno B, Zhang MJ, Fei M, Diaz MA, Copelan E, Ganguly S, Hamadani M, Kharfan-Dabaja M, Lazarus H, Lee C, Meehan K, Nishihori T, Saad A, Seo S, Ramanathan M, Usmani SZ, Gasparetto C, Mark TM, Nieto Y, Hari P. Autologous/Allogeneic Hematopoietic Cell Transplantation versus Tandem Autologous Transplantation for Multiple Myeloma: Comparison of Long-Term Postrelapse Survival. Biol Blood Marrow Transplant. 2018 03; 24(3):478-485.
    View in: PubMed
    Score: 0.018
  9. Sonneveld P, Avet-Loiseau H, Lonial S, Usmani S, Siegel D, Anderson KC, Chng WJ, Moreau P, Attal M, Kyle RA, Caers J, Hillengass J, San Miguel J, van de Donk NW, Einsele H, Blad? J, Durie BG, Goldschmidt H, Mateos MV, Palumbo A, Orlowski R. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood. 2016 06 16; 127(24):2955-62.
    View in: PubMed
    Score: 0.016
  10. Hamadani M, Abu Kar SM, Usmani SZ, Savani BN, Ayala E, Kharfan-Dabaja MA. Management of relapses after hematopoietic cell transplantation in T-cell non-Hodgkin lymphomas. Semin Hematol. 2014 Jan; 51(1):73-86.
    View in: PubMed
    Score: 0.014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.